Dublin, April 12, 2016 -- Research and Markets has announced the addition of Jain PharmaBiotech's new report "Therapeutic Drug Monitoring - Technologies, Markets, and Companies" to their offering.
This report deals with therapeutic drug monitoring, a multi-disciplinary clinical specialty, aimed at improving patient care by monitoring drug levels in the blood to individually adjust the dose of drugs for improving outcome. TDM is viewed as a component of personalized medicine that interacts with several other disciplines including pharmacokinetics and pharmacogenetics. One chapter is devoted to monitoring of drugs of abuse (DoA). Various technologies used for well-known DoA are described.
A section on drug abuse describes methods of detection of performance-enhancing drugs. TDM market is analyzed from 2015 to 2025 according to technologies as well as geographical distribution. Global market for DoA testing was also analyzed from 2015 to 2025 and divided according to the area of application. Unmet needs and strategies for development of markets for TDM are discussed.
The report contains profiles of 27 companies involved in developing tests and equipment for drug monitoring along with their collaborations. The text is supplemented with 18 tables, 6 figures and 190 selected references from literature.
Who should read this report?
- Biotechnology companies developing assays and equipment for drug monitoring.
- Reference laboratories providing drug monitoring services.
- Pharmaceutical companies interested in companion tests for monitoring their drugs.
- Clinical pharmacologists interested in integrating therapeutic drug monitoring with pharmacogenetics for development of personalized medicine.
Key Topics Covered:
Executive Summary
1. Introduction
2. Technologies for TDM
3. Drug Monitoring Instruments
4. Applications of TDM
5. Drugs Requiring Monitoring
6. Monitoring of Biological Therapies
7. Monitoring of Drug Abuse
8. Markets for TDM
9. Companies
10. References
For more information visit http://www.researchandmarkets.com/research/d48q5h/therapeutic_drug
Source: Jain PharmaBiotech
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Drug Discovery


Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment
Washington Post Publisher Will Lewis Steps Down After Layoffs
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 



